

DAFTAR PUSTAKA

1. Biron BM, Ayala A, Neira JL. Biomarkers for sepsis: what is and what might be?. *Biomarker Insights*. 2015;10(4):7-17.
2. Singer M, Annane D, Coopersmith CM, Opal SM. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
3. Bochud PY, Calandra. Pathogenesis of sepsis. *Br Med J*. 2003;326:262-6.
4. Russell J. Management of sepsis. *N Eng J Med*. 2006;355:1699-713.
5. Irwan I. Korelasi kadar laktat darah dan C-Reactive Protein terhadap disfungsi multipel yang diukur dengan skor SOFA pada pasien sepsis yang dirawat di ICU [Tesis]. Makassar: Universitas Hasanuddin; 2012.
6. Rajab R. Hubungan kadar laktat dengan disfungsi organ multipel pada pasien sepsis di Makassar [Tesis]. Makassar: Universitas Hasanuddin; 2012.
7. Hoeboer SH. Biomarkers of infection and its complications in the critically ill [Thesis]. Netherland: University Amsterdam; 2015.
8. Abidi K, Khoudri I, Belayachi J. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. *Crit Care*. 2008;12(2):R59.
9. Gil H, Magy N, Mauny F. Value of eosinopenia in inflammatory disorders: an 'old' marker revisited. *Rev Med Interne*. 2003;24:431-5.
10. Vincent JL, Moreno R, Takala J. The SOFA (sepsis related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. *Intensive Care Med*. 1996;22:707-10.
11. Levy MM, Fink MP, Marshall. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. *Intensive Care Med*. 2003;29:530-8.
12. Carrigan SD, Scott G. Toward resolving the challenges of sepsis diagnosis. *Clin Chem J*. 2004; 50:1301-14.
13. Russell J. Management of sepsis. *N Eng J Med*. 2006;355:1699-713.
14. ...BL. Identification and management the patients with sepsis. *Crit Med*. 2001;46:436-64.
15. Takeda K. Toll like receptors: critical protein linking innate and ... immunity nature. *Immunology*. 2001;2:679-83.



16. Hotchkiss R, Karl I. The pathophysiology and treatment of sepsis. *N Eng J Med.* 2003;348:138-50.
17. Annane D, Bellissant E, Cavailon JM. Septic Shock. *Lancet.* 2005;365:63-78.
18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock 2012. *Crit Care Med J.* 2013;39:165-228.
19. Berkwits M. Consensus definition for sepsis and septic shock. *JAMA.* New York; 2016.
20. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. *Antimicrob Chemother.* 2011;66(2):33-40.
21. Pieteris L, Baksyte G, Cesnaitis T, Vitkauskiene A, Macas A. New strategies in sepsis diagnosis. *Acta Medica Lituanica.* 2012;19(3):160-2.
22. Hoeboer SH. Biomarkers of infection and its complications in the critically ill [Thesis]. Netherland: University Amsterdam; 2015.
23. Ahmadinejad Z. Evaluation of serum procalcitonin in patients with systemic inflammatory response syndrome with and without infection. *Acta medica Iranica.* 2009;47:50383-8.
24. Soreng, Katherin, Levy, Roma MS. Procalcitonin: an emerging biomarker of bacterial sepsis. *Clin Microbiol Newsletter.* 2011;33(22):171-8.
25. Fioretto JR. Interleukin-6 and procalcitonin in children with sepsis and septic shock. *Cytokine.* 2008;43:160-4.
26. Zhao D. Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac surgery. *China J Intensive Care.* 2014;2:35-41.
27. Jin M, Khan, Adil I. Procalcitonin: use in the clinical laboratory for the diagnosis of sepsis. *Lab medicine.* 2010;41(3):173-7.
28. Carrol ED. Review: procalcitonin as a marker of sepsis. *Inter J Antimicrobial Agent.* 2002;20:1-9.

, Ibrahim, Ahamed BU. Procalcitonin versus C-reactive protein
 as biomarker of sepsis in ICU patient. *NCBI.* 2014;8:1-7.

JR, Torres OJ, Czczko NG. Procalcitonin as a prognostic



- biomarker of severe sepsis and septic shock. Rev Col Bras Cir. 2012;39(6):456-60.
31. Rajkumari N, Mathur P, Sharma S. Procalcitonin as a predictor of sepsis and outcome in severe trauma patients. J Lab Phys. 2013;5(2):100-8.
32. Zhao D. Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac surgery. China J Intensive Care. 2014;2:35-41.
33. Shehabi Y, Sterba M, Garret PM. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. Am J Respi Crit Care Med. 2014;190(10):1102-10.
34. Karlsson S, Heikkinen M, Pattila V. Predictive value of procalcitonin decrease in patients with severe sepsis. Crit Care. 2010;14:1-10.
35. Jin M, Khan, Adil I. Procalcitonin: Use in the clinical laboratory for the diagnosis of sepsis. Lab Medicne. 2010;41(3):173-7.
36. Levy MM, Fink MP, Marshall. SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Intensive Care Med. 2003;29:530-8.
37. Szederjesi J, Almasy E, Lazar A. An evaluation of serum procalcitonin and C-Reactive Protein levels as diagnostic and prognostic biomarkers of severe sepsis. J Crit Care Med. 2015;1(4):147-53.
38. Lopez FR, Jimenez AE, Tobon GC. Procalcitonin (PCT), C reactive protein (CRP) and its correlation with severity in early sepsis. Clin Rev Opinions. 2011; 3(3):26-31.
39. Clapp BR, Hirschfield GM, Storry C. Inflammation and endothel function direct vascular effect of human C-reactive protein on nitric oxide bioavailability. Circulation. 2005;111:1530-6.
40. Trzeciak S, EP R. Clinical manifestations of disordered microcirculatory perfusion in severe sepsis. Crit Care Med. 2005;9:20-6.
41. Johnson D, Mayers I. Multiple organ dysfunction syndrome : a narrative review. Can J Anaest. 2001;20:502-08.
42. Horwanto V, Amin Z. Sindrom disfungsi organ multipel: patofisiologi dan sis. Maj Kedokt Indon. 2009;59(11):548-54.
- FL, Bota DP, Bross A, Vincent JL. Serial evaluation of the SOFA to predict outcome in critically ill patients. JAMA. 2001;286:1754-



- 8.
44. Acharya SP, Pradhan B, Marhatt MN. Application of the sequential organ failure assessment (SOFA) score in predicting outcome in ICU patients with SIRS. *Kathmandu Univ Med J.* 2007;5(4):475-83.
45. Cholongitas E, Senzolo M, Shaw S. Review article: scoring systems for assessing prognosis in critically ill adult cirrhotics. *Aliment Pharmacol Ther.* 2006;24:453-64.
46. Jones AE, Trzeciak S, Kline JA. The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med.* 2009;37(5):1649-54.
47. Neto AO, Parpinelli MA, Cecatti JG. Sequential organ failure assessment score for evaluating organ failure and outcome of severe maternal morbidity in obstetric intensive care. *Sci World J.* 2012.
48. Rothenberg ME, Hogan SP. The eosinophil. *Annu Rev Immunol.* 2006;24:147-74.
49. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. *Pharm Rev* 1999;51(2):213-339.
50. Lokhandwala A, Athar S, Turrin NP. Role of absolute eosinopenia as marker of enteric fever : experience from a tertiary care hospital in the United Arab Emirates. *Ibnosina J Med.* 2012;4(6):249-53.
51. Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia : Is it a good marker of sepsis in comparison to procalcitonin and c-reactive protein levels for patients admitted to a critical care unit in an urban hospital?. *J Crit Care* 2010;25(4):570-5.
52. Yefta EK, Yuniati T, Rahayuningsih SE. Validitas eosinopenia sebagai penanda diagnosis pada sepsis neonatal bakterialis. *Maj Kedokt Indon* 2009;59(12):601-6.
53. Kim YH, Park HB, Kim MJ, Kim HS, Lee HS, Han YK, dkk. Prognostic usefulness of eosinopenia in the pediatric intensive care unit. *J Korean Med Sci.* 2013;28:114-9.



54. Jagdeesh TS, Mishra A, Saxena A, Sharma D. Eosinopenia as a prognostic marker in patients with peritonitis. *ISRN Infectious Diseases*. 2013:article ID 540948.
55. Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, et al. Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia : a retrospective cohort study. *PLoS ONE*. 2012;7(8):e42860.
56. Akuthota P, Weller PF. Spectrum of eosinophilic end-organ manifestations. *Immunol Allergy Clin North Am*. 2015;35(3):403-11.
57. Farid M. Korelasi Kadar Laktat Darah dan *C-Reactive Protein* terhadap Skor SOFA pada Pasien Pasca Bedah Cedera Otak Traumatik Berat yang Dirawat di ICU [Tesis]. Makassar: Universitas Hasanuddin; 2019.
58. Primadonna. Eosinopenia Sebagai Prediktor Disfungsi Organ Pada Pasien Sepsis Dan Syok Sepsis Di ^[ICU]*Intensive Care Unit* (ICU) [Tesis]. Makassar: Universitas Hasanuddin; 2019.
59. Sunaryo A, Redjeki SI, Bisri T. Perbandingan validasi APACHE II dan SOFA score untuk memperkirakan mortalitas pasien yang dirawat di unit perawatan intensif. *Juni 2013*;1(2):11-20.
60. Delarica AS, Maseda E, Anillo V et al. Biomarkers (Procalcitonin, C-Reactive Protein, and Lactate) as Predictors of Mortality in Surgical Patients With Complicated Intra-Abdominal Surgery. *Surg Inf*. 2015; (16):3

